The Vaccinia-based Sementis Copenhagen Vector Coronavirus Disease 2019 Vaccine Induces Broad and Durable Cellular and Humoral Immune Responses

Overview

Journal Immunol Cell Biol

Publisher Wiley

Specialties Allergy & Immunology
Cell Biology

Date 2022 Feb 21

PMID 35188985

Authors

Preethi Eldi

Tamara H Cooper

Natalie A Prow

Liang Liu

Gary K Heinemann

Voueleng J Zhang

Abigail D Trinidad

Ruth Marian Guzman-Genuino

Peter Wulff

Leanne M Hobbs

Kerrilyn R Diener

John D Hayball

Affiliations

Soon will be listed here.

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic perpetuated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus-based, replication-defective Sementis Copenhagen Vector (SCV) was used to develop a first-generation COVID-19 vaccine encoding the spike glycoprotein (SCV-S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust type 1 T helper-biased, spike-specific antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated that neutralizing antibody activity was maintained up to 9 months after vaccination in both young and middle-aged mice, with durable immune memory evident even in the presence of pre-existing vector immunity. Therefore, SCV-S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second-generation SCV-based COVID-19 vaccine candidates incorporating additional SARS-CoV-2 immunogens.

References

Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O . A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A. 2021; 118(12). PMC: 8000430. DOI: 10.1073/pnas.2026153118. View

Tarke A, Sidney J, Methot N, Yu E, Zhang Y, Dan J . Impact of SARS-CoV-2 variants on the total CD4 and CD8 T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021; 2(7):100355. PMC: 8249675. DOI: 10.1016/j.xcrm.2021.100355. View

Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L . Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020; 109(5):531-538. PMC: 7087935. DOI: 10.1007/s00392-020-01626-9. View

Yadav P, Sapkal G, Abraham P, Ella R, Deshpande G, Patil D . Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees. Clin Infect Dis. 2021; 74(2):366-368. DOI: 10.1093/cid/ciab411. View

Taylor S, Hurst B, Charlton C, Bailey A, Kanji J, McCarthy M . A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. J Clin Microbiol. 2021; 59(4). PMC: 8092720. DOI: 10.1128/JCM.02438-20. View

Tseng C, Sbrana E, Iwata-Yoshikawa N, Newman P, Garron T, Atmar R . Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012; 7(4):e35421. PMC: 3335060. DOI: 10.1371/journal.pone.0035421. View

Mlcochova P, Kemp S, Dhar M, Papa G, Meng B, Ferreira I . SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021; 599(7883):114-119. PMC: 8566220. DOI: 10.1038/s41586-021-03944-y. View

Hazlewood J, Dumenil T, Le T, Slonchak A, Kazakoff S, Patch A . Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures. PLoS Pathog. 2021; 17(1):e1009215. PMC: 7837487. DOI: 10.1371/journal.ppat.1009215. View

Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F . Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. Clin Infect Dis. 2020; 71(15):896-897. PMC: 7184372. DOI: 10.1093/cid/ciaa415. View

10.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

11.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

12.

Tscherne A, Schwarz J, Rohde C, Kupke A, Kalodimou G, Limpinsel L . Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Proc Natl Acad Sci U S A. 2021; 118(28). PMC: 8285915. DOI: 10.1073/pnas.2026207118. View

13.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

14.

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J . Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021; 592(7854):438-443. DOI: 10.1038/s41586-021-03402-9. View

15.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

16.

Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M . A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011; 85(23):12201-15. PMC: 3209347. DOI: 10.1128/JVI.06048-11. View

17.

Viegas E, Kroidl A, Munseri P, Missanga M, Nilsson C, Tembe N . Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. PLoS One. 2018; 13(11):e0206838. PMC: 6264478. DOI: 10.1371/journal.pone.0206838. View

18.

Tanriover M, Doganay H, Akova M, Guner H, Azap A, Akhan S . Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021; 398(10296):213-222. PMC: 8266301. DOI: 10.1016/S0140-6736(21)01429-X. View

19.

Liu L, Cooper T, Howley P, Hayball J . From crescent to mature virion: vaccinia virus assembly and maturation. Viruses. 2014; 6(10):3787-808. PMC: 4213562. DOI: 10.3390/v6103787. View

20.

Malherbe D, Kurup D, Wirblich C, Ronk A, Mire C, Kuzmina N . A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19. NPJ Vaccines. 2021; 6(1):91. PMC: 8298481. DOI: 10.1038/s41541-021-00352-1. View